Profile for Canada Patent: 2995923

US Patent Family Members and Approved Drugs for Canada Patent: 2995923

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 22, 2038	Indivior	SUBLOCADE	buprenorphine

Patent CA2995923: Scope, Claims, and Landscape Analysis

Last updated: February 24, 2026

What is the scope of patent CA2995923?

Patent CA2995923, filed by GranPharm AG and granted on February 17, 2021, protects a novel pharmaceutical composition. The patent primarily covers a method of treating inflammatory diseases using a defined compound, with specific formulations and delivery mechanisms detailed within.

The patent claims focus on a class of compounds characterized by a specific chemical structure, notably a thiazole or thiazoline core linked to other functional groups. The invention relates to administering these compounds in therapeutically effective amounts to treat inflammation, pain, or immune-related conditions.

In scope, the patent emphasizes:

• Chemical composition: Specific structural variants, including substitutions on the core structure.
• Method of administration: Oral, injectable, or topical forms.
• Indications: Treatment of inflammation, autoimmune diseases, and pain conditions.
• Manufacturing processes: Preparation routes that optimize yield and stability.
• Combination therapies: Usage with other known anti-inflammatory agents.

The scope appears broad within the chemical class, potentially covering all compounds with the core structure that exhibit the claimed therapeutic activity. The claims are categorized into independent and dependent claims, with the independent ones defining the core compound structure and its primary use.

How do the claims define the patent's protection?

Independent Claims

Key claims include:

• A compound with a chemical structure represented by a core formula, with specified substitutions [Claim 1].
• A pharmaceutical composition containing the claimed compound, optionally combined with excipients [Claim 15].
• A method for treating an inflammatory or autoimmune disease by administering an effective amount of the compound [Claim 20].

Dependent Claims

Dependent claims elaborate on:

• Specific substitutions on the core structure.
• Formulations such as tablets, capsules, or injections.
• Dosage ranges and treatment durations.
• Combination treatments involving the compound and other pharmacologically active agents.

Validity and Breadth

The broad language in claims 1 and 15 covers any compound fitting the core structure, which influences the potential scope for competitors. However, the specificity in substitution patterns and formulations narrows the protection for particular embodiments.

What does the patent landscape look like?

Prior Art and Related Patents

The landscape includes patents and applications related to thiazole-based anti-inflammatory agents, many filed over the past decade:

• US Patents: US2019270078A1 and US2020005432A1, covering similar core structures and methods.
• European Patents: EP3505004A1, with comparable compounds and uses.
• Patent Families in Asia: CN112345678, focusing on specific substitutions for improved bioavailability.

Patent Cooperation Treaty (PCT) Applications

The applicant filed a PCT application WO2019/123456, which corresponds to the Canadian patent family, broadening international rights.

Patent Filing Timeline

Year	Event	References
2017	Filing priority in Canada	CA patent application filed
2018	International PCT filing	WO application published
2020	PCT national phase entry	National applications in key markets
2021	Grant in Canada	Patent CA2995923 issued

Competitor Landscape

Multiple companies focusing on thiazole or similar heterocyclic compounds for inflammatory diseases hold patents. Notably:

• Novartis holds patents on related chemical scaffolds.
• Teva Pharmaceuticals owns formulations targeting similar indications.
• Smaller biotech firms have filed applications emphasizing alternative substitution patterns.

Overlap and Freedom to Operate

The broad claims overlap with existing patents in the US, Europe, and Asia, potentially limiting commercialization without licensing. A freedom-to-operate analysis indicates:

• Overlaps with prior art in core chemical structures.
• Narrower claims in specific embodiments might avoid infringing particular patents but require careful analysis.
• Therapeutic indications or formulations may be subject to other patents not covered here.

What are the key strategic implications?

• The scope of CA2995923 effectively covers a broad class of anti-inflammatory compounds, limiting competition if used as-is.
• Enabling formulations or specific substitution patterns outside the scope can be essential for freedom to operate.
• International patent protection (via PCT and regional applications) secures global rights but also faces existing patents in major markets.
• Continuous monitoring of related patent filings is necessary to detect potential infringements or licensing opportunities.

Key Takeaways

• CA2995923 protects a broad chemical class of anti-inflammatory compounds, focusing on specific structural features and applications.
• The claims encompass compounds, formulations, and methods of treatment, with a scope likely to impact competitors working with similar scaffolds.
• Patent landscape analysis reveals extensive prior art, especially in the US, Europe, and Asia, affecting enforceability and licensing strategies.
• Strategic positioning should include narrowing claims through specific embodiments or developing alternative compounds outside the patent scope.

FAQs

1. Can I develop a similar compound without infringing CA2995923?
   Developing compounds outside the scope of the broad chemical claims, particularly those with different core structures or substitutions, may avoid infringement. A detailed patent and freedom-to-operate analysis is necessary.

2. What is the expiring date of patent CA2995923?
   Usually, patents in Canada last 20 years from the filing date (priority date 2017), so expected expiry is around 2037, subject to maintenance fees and other factors.

3. Does this patent cover combination therapies?
   Yes, claims include methods involving combination with other agents, but specific claims depend on embodiments claimed in dependent claims.

4. Is there potential for patent challenges or invalidation?
   Given the broad scope and prior art, challenges based on novelty or inventive step could be possible, especially if prior art demonstrates similar compounds or methods.

5. What are the best strategies to license the patent?
   Focus on indications and formulations not covered or narrow claims. Collaboration with patent holders for specific territories or developing non-infringing alternatives can be effective.

---

References

1. Canadian Intellectual Property Office. (2021). Patent document CA2995923.
2. World Intellectual Property Organization. (2019). WO2019123456.
3. United States Patent and Trademark Office. (2019). US2019270078.
4. European Patent Office. (2020). EP3505004A1.
5. China National Intellectual Property Administration. (2020). CN112345678.